150 related articles for article (PubMed ID: 29129444)
21. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients.
Shin SH; Kim SC; Song KB; Hwang DW; Lee JH; Park KM; Lee YJ
Surgery; 2018 Sep; 164(3):432-442. PubMed ID: 29884479
[TBL] [Abstract][Full Text] [Related]
22. What is the major prognostic factor in tumor-node-metastasis staging of pancreatic adenocarcinoma?
Santi I; Brandt A; Hemminki K
Ann Surg Oncol; 2011 Jan; 18(1):300-1. PubMed ID: 20589435
[No Abstract] [Full Text] [Related]
23. Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival.
Holm M; Saraswat M; Joenväärä S; Seppänen H; Renkonen R; Haglund C
Tumour Biol; 2020 Jun; 42(6):1010428320936410. PubMed ID: 32586207
[TBL] [Abstract][Full Text] [Related]
24. Adverse oncologic effects of intraoperative transfusion during pancreatectomy for left-sided pancreatic cancer: the need for strict transfusion policy.
Hwang HK; Jung MJ; Lee SH; Kang CM; Lee WJ
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):497-507. PubMed ID: 27295957
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic volume is one of the independent prognostic factors for resectable pancreatic ductal adenocarcinomas.
Fukumoto T; Watanabe T; Hirai I; Kimura W
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):472-9. PubMed ID: 27246905
[TBL] [Abstract][Full Text] [Related]
26. The treatment of pancreatic cancer.
Yeo CJ; Cameron JL
Ann Chir Gynaecol; 2000; 89(3):225-33. PubMed ID: 11079793
[No Abstract] [Full Text] [Related]
27. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma.
Sakugawa C; Haruyama Y; Tanaka H; Fukushima T; Kawaguchi M; Kataoka H
BMC Res Notes; 2017 Dec; 10(1):674. PubMed ID: 29202869
[TBL] [Abstract][Full Text] [Related]
29. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.
Liu J; Jiang W; Zhao K; Wang H; Zhou T; Bai W; Wang X; Zhao T; Huang C; Gao S; Qin T; Yu W; Yang B; Li X; Fu D; Tan W; Yang S; Ren H; Hao J
J Exp Med; 2019 Mar; 216(3):656-673. PubMed ID: 30733283
[TBL] [Abstract][Full Text] [Related]
30. A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma.
Lim KH; Langley E; Gao F; Luo J; Li L; Meyer G; Kim P; Singh S; Kushnir VM; Early DS; Mullady DK; Edmundowicz SA; Wani S; Murad FM; Cao D; Azar RR; Wang-Gillam A
Oncotarget; 2017 Apr; 8(15):24250-24261. PubMed ID: 28445954
[TBL] [Abstract][Full Text] [Related]
31. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
32. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
Hackert T; Ulrich A; Büchler MW
Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
[No Abstract] [Full Text] [Related]
33. Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas.
Handra-Luca A; Hong SM; Walter K; Wolfgang C; Hruban R; Goggins M
Br J Cancer; 2011 Apr; 104(8):1296-302. PubMed ID: 21448168
[TBL] [Abstract][Full Text] [Related]
34. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.
Philip PA; Mooney M; Jaffe D; Eckhardt G; Moore M; Meropol N; Emens L; O'Reilly E; Korc M; Ellis L; Benedetti J; Rothenberg M; Willett C; Tempero M; Lowy A; Abbruzzese J; Simeone D; Hingorani S; Berlin J; Tepper J
J Clin Oncol; 2009 Nov; 27(33):5660-9. PubMed ID: 19858397
[TBL] [Abstract][Full Text] [Related]
35. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer.
Abe T; Ohuchida K; Endo S; Ookubo F; Mori Y; Nakata K; Miyasaka Y; Manabe T; Ohtsuka T; Nagai E; Oda Y; Nakamura M
Surgery; 2017 Apr; 161(4):951-958. PubMed ID: 27939334
[TBL] [Abstract][Full Text] [Related]
36. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
37. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma.
Takahashi H; Ogawa H; Ohigashi H; Gotoh K; Yamada T; Ohue M; Miyashiro I; Noura S; Kishi K; Motoori M; Shingai T; Nakamura S; Nishiyama K; Yano M; Ishikawa O
Surgery; 2011 Sep; 150(3):547-56. PubMed ID: 21621236
[TBL] [Abstract][Full Text] [Related]
38. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers in pancreatic ductal adenocarcinoma.
Gallego J; López C; Pazo-Cid R; López-Ríos F; Carrato A
Clin Transl Oncol; 2017 Dec; 19(12):1430-1437. PubMed ID: 28616721
[TBL] [Abstract][Full Text] [Related]
40. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
